• Resources
  • About
  • Events
    • Upcoming Events
    • Archived Events
  • The ORBCoN Report
  • Bloody Easy E-Tools & Publications
    • Bloody Easy Blood Administration (BEBA)
    • Bloody Easy for Healthcare Professionals
    • Bloody Easy Lite
    • ORBCoN Tech Assess
  • Blood Utilization & Audits
    • Audits Tools
    • Blood Utilization Graphs
    • COPTN Reports
    • O Negative RBC Utilization
    • Provincial Audit Reports
  • IVIG/SCIG
  • Massive Hemorrhage Protocol
    • eLearning
    • Provincial MHP Toolkit
    • Supplementary Resources
    • Recommendation Statements
  • ORBCoN Resources
    • Helpful Apps
    • The ORBCoN Report
    • Order Resources
    • Presentation Library
  • Toolkits
    • Bedside Audit
    • Dispensary and Administration
    • Emergency Blood Management
    • Home Infusion Toolkit
    • Implementing an Evaluation Process for your Transfusion Medicine Lab Competency Assessment Program (CAP)
    • Inventory Management
    • New Product
    • OTTRM
    • Resources for Midwives
    • Special Blood Requirements
    • Transporting Blood Internally
    • Transfusion Committee
    • Transfusion Safety Officer Resource Manual
    • Quality Improvement Plan
  • TM Guidelines, Standards, & Recommendations
    • Guidelines
    • NAC Guidelines and Recommendations
    • Recommendations
    • Resource Manual for Medical Directors of Transfusion Medicine
    • Standards
  • Quality Improvement
Home » IVIG/SCIG » Utilization Management Guidelines »

Kawasaki Disease

Recommended Indications in which IG can be used

Order Number: R6-KD

RecommendationsIVIG is recommended when Kawasaki diagnosis confirmed.
Dose/Frequency of Administration2 g/kg for 1 day (second dose can be given for patients who fail to respond to initial dose).
  • Utilization Management Guidelines

    Rheumatology

    • Antiphospholipid syndrome – catastrophic
    • Antiphospholipid syndrome (other than catastrophic)
    • Autoimmune retinopathy (AIR)
    • Behçet disease
    • Eosinophilic granulomatosis with polyangiitis (EGPA) (Churg–Strauss disease)
    • Idiopathic Inflammatory myopathy (IIM)
    • Inclusion body myositis (IBM)
    • Juvenile Idiopathic Inflammatory Myopathy (J-IIM)(Previously Juvenile Dermatomyositis)
    • Kawasaki Disease
    • Macrophage activation syndrome (MAS)
    • Multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2/COVID-19 infection
    • Rheumatoid arthritis

© 2025 Copyright: Ontario Regional Blood Coordinating Network

    • Contact
    • Order Resources
    • Careers
    • Useful Links
    • Privacy
    • Legal
Subscribe to our newsletter
    • Contact
    • Order Resources
    • Careers
    • Useful Links
    • Privacy
    • Legal
Subscribe to our newsletter

© 2025 Copyright: Ontario Regional Blood Coordinating Network